Women | Men | |||||
---|---|---|---|---|---|---|
Stroke (n=145) | No stroke (n=1286) | p Value | Stroke (n=180) | No stroke (n=1233) | p Value | |
CHA2DS2-VASc score, % (n) | ||||||
0 | 13.8 (20) | 38.7 (497) | <0.0001 | 10.6 (19) | 34.1 (421) | <0.0001 |
1 | 17.2 (25) | 26.4 (340) | 40.6 (73) | 41.9 (517) | ||
2 | 11.7 (17) | 8.9 (115) | 36.7 (66) | 19.2 (237) | ||
3 | 44.1 (64) | 23.1 (297) | 8.3 (15) | 4.3 (53) | ||
4 or more | 13.1 (19) | 2.9 (37) | 3.9 (7) | 0.4 (5) | ||
LA size indexed by BSA (cm/m2) | ||||||
<2.2 | 37.0 (50) | 53.1 (658) | <0.0001 | 54.1 (92) | 63.6 (762) | 0.014 |
2.2–2.79 | 47.4 (64) | 42.3 (524) | 41.8 (71) | 34.8 (417) | ||
≥2.8 | 15.6 (21) | 4.7 (58) | 4.1 (7) | 1.7 (20) | ||
Atrial fibrillation (AF) | ||||||
AF, % (n) | 26.9 (39) | 12.5 (161) | <0.0001 | 19.4 (35) | 17.7 (218) | 0.564 |
AF before or until up to date of stroke, % (n) | ||||||
No AF | 73.1 (106) | 87.5 (1125) | <0.0001 | 80.6 (145) | 82.3 (1015) | 0.329 |
Paroxysmal/persistent AF | 12.4 (18) | 5.5 (71) | 6.7 (12) | 8.0 (99) | ||
Permanent AF | 14.5 (21) | 6.6 (85) | 12.8 (23) | 9.0 (111) | ||
Unclassified AF | 0 | 0.4 (5) | 0 | 0.7 (8) | ||
AF after stroke, % (n) | ||||||
No AF | 81.1 (86) | 84.8 (123) | ||||
Paroxysmal/persistent AF | 10.4 (11) | 6.9 (10) | ||||
Permanent AF | 8.5 (9) | 7.6 (11) | ||||
Unclassified AF | 0 | 0.7 (1) |
Percentage (number of participants). The Tromsø Study 1994–1995.